Cabergoline is named as an intervention in 9 current clinical trials in our Denmark, China, Sweden, Norway, Switzerland, Brazil, Taiwan, Australia and Egypt registers. 5 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Changchun GeneScience Pharmaceutical Co., Ltd (1). The most-studied condition is Prolactinoma. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Cabergoline was first approved in the US on 23 Dec 1996. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Cabergoline. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Prevention and Treatment of Episodic migraine by Cabergoline Therapy (PROTECT)
A randomized, placebo-controlled, double-blind, investigator-initiated trial
2025-522323-10-00 · CTIS ↗ · Nervous System Diseases
|
Phase 3 | Ongoing | Region Midtjylland | Denmark |
|
CARESS Study: Cabergoline for the Reduction of Endometriosis Symptoms and Lesion Size
2025-522812-18-00 · CTIS ↗ · Female Urogenital Diseases and Pregnancy Complications
|
Phase 3 | Authorised | Hospital Clinico San Carlos | Spain |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
8 single-substance products containing Cabergoline on the HPRA medicines list.
| Condition (as registered) | Trials |
|---|---|
| Prolactinoma | 2 |
| Hyperprolactinemia | 1 |
| Pituitary Neoplasms | 1 |
| Adenoma | 1 |
| Scizophrenia | 1 |
| Migraine | 1 |
| Prolactin Excess | 1 |
| Pituitary Adenoma | 1 |
| MRI | 1 |
| RCT | 1 |
| Erectile Dysfunctions | 1 |
| Healthy Volunteer | 1 |
| Gynecologic Disease | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
9 current trials in our Denmark, China, Sweden, Norway, Switzerland, Brazil, Taiwan, Australia and Egypt registers name Cabergoline (also registered as FCE 21336) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 9 trials are recruiting: 1 with sites in Denmark, 1 with sites in China, 1 with sites in Switzerland, 1 with sites in Brazil and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Changchun GeneScience Pharmaceutical Co., Ltd (1), St. Olavs Hospital (1), Zealand University Hospital (1) and Aarhus University Hospital (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 8 single-substance products containing Cabergoline, for example Cabaser 1 mg Tablet (Pfizer Healthcare Ireland Unlimited Company). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 4 entries for Cabergoline: 4 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cabergoline works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cabergoline works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cabergoline (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.